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LETTERS TO THE EDITOR
The Role of
Postoperative
Radiotherapy After
Resection of Stage
III Thymoma
To the Editor:
We read with interest the article by
Chang et al.1 entitled “Postoperative ra-
diotherapy for completely resected stage II
and III thymoma.” They retrospectively
reviewed their 20-year experience with
surgery for epithelial thymic tumors. Their
study group included 76 patients, 59 with
stage II thymoma, but unfortunately only
11 at stage III. Other 50 patients operated
on at their center were excluded from the
study mainly because data were insuffi-
cient. There were 11 patients with addi-
tional metachronous malignancies. The
median follow-up, notwithstanding the
20-year study period, was only 56 months
(5 years). In patients with stage III tu-
mors, 3 of 11 (27%) had recurrence. The
conclusion of the authors was that postop-
erative radiotherapy alone was sufficient
in patients with completely resected inva-
sive thymoma. Exclusion of a large num-
ber of patients (50 patients) may contrib-
ute to decrease in the accuracy of the
study, as often patients lost to follow-up
are those doing worse. In addition, it is not
clear from the text whether patients with
metachronous cancer received chemother-
apy, as reported by other groups.2
We believe that it is incorrect and
potentially misleading, especially for res-
idents and surgeons who face this problem
less often, to draw these conclusions on
the base of the data reported in this retro-
spective study, in particular concerning
patients with stage III thymoma. There
were only 11 patients at this stage and 3
(27%) had recurrence. This is a very
small group, probably the smallest re-
ported in the recent literature. Stage III
tumors require a multidisciplinary ap-
proach, often including both induction
(never required in this small group of
patients) and postoperative treatment, po-
tentially including chemo- and radiother-
apy. Radiotherapy alone has often been
demonstrated insufficient at stage III,3 and
also at stage II, when histology is B3 or C,
or when the mediastinal fat is extensively
infiltrated, chemotherapy has been advo-
cated by our group,4 greatly contributing
to improve outcome.
We would like to ask the authors
whether patients with metachronous cancer
received chemotherapy and whether there
was any recurrence in this group. We would
also like them to comment on the limitations
of their retrospective study that we previ-
ously remarked.
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In Reply:
We excluded 50 patients from
the study not because of lost follow-
ups (we have investigated the status of all
the included patients) but because of in-
sufficient data in their old records or treat-
ments (e.g., missing operation date, start/
end day of radiation, unclear margin status
of the pathology report, or incomplete ra-
diation). Those can be minor problems,
and the data might have been helpful in
increasing the total number of patients in
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TABLE 1. Detailed Information on Patients with Additional Malignancies
Patient
No. Treatment
Masaoka
Stage
Other Primary
Malignancies
Time Relation
with Thymoma
Time
Intervals Chemotherapy
1a Op alone II Prostate Post 3 yr No
2 Op alone II Non-small cell lung
cancer
Post 1.5 yr No
3 Op alone II Advanced gastric cancer Post 6 yr Yes
4 Op alone III Small cell lung cancer Pre 4 yr Yes
5 Op alone III Non-Hodgkins
lymphoma
Pre 5.5 yr Yes
6 Op  RT II Acute lymphoblastic
leukemia
Post 8 mo Yes
7 Op  RT III Cervix cancer Pre 1.5 yr No
8 Op  RT II Esophageal cancer Post 4 yr Yes
9 Op  RT II Malignant fibrous
histiocytoma
Pre 5 mo No
10 Op  RT II Prostate cancer Post 6 mo No
11 Op  RT II Breast cancer Pre 3 mob Yes
a Patient with recurrent thymoma.
b In patient 11, breast cancer and thymoma can be considered as synchronous cancer.
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this study, but we decided to leave them
out to enhance the reliability of the results.
As mentioned in the article, this
study is a retrospective study, due to
which it has limitations.1 We tried to im-
prove the data homogeneity, however, by
applying strict inclusion criteria as much
as we could to overcome the effect of
differences in the treatments between the
past and the present.
The main topic of our article was
the necessity of adjuvant radiation therapy
in the completely resected invasive thy-
moma, including stages II and III thy-
moma. Furthermore, unlike in the study of
Venuta et al, we did not cover thymic
carcinoma and incompletely resected tu-
mors in the study.2 It would be difficult to
compare our article with the article on the
results of the study by Venuta et al. because
the characteristics of the tumor are very
different. It is well known that in an
inoperable thymoma or thymic carci-
noma, chemotherapy might be needed in
the neoadjuvant/adjuvant setting. However,
both were not the objects of this study.
Therefore, it was not important to mention
chemotherapy. Moreover, it is difficult to
tell the relationship between chemother-
apy and its absence after metachronous
cancer, and the outcome of invasive thy-
moma, because there are various differ-
ences between the patients (Table 1).
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A Practical Guide to
Measure “All”
Malignant Pleural
Mesothelioma Tumors
by Modified RECIST
Criteria?
To the Editor:
We read with interest the practical
guidelines offered by Tsao et al.1 on
how to make measurements of malig-
nant pleural mesothelioma (MPM) by
modified RECIST criteria. When we
try to make a diagnosis of MPM, we
usually rely on a combination of clin-
ical characteristics, of radiological and
(more recently also) nuclear imaging
findings together with a confirmatory
pleural biopsy and/or pleural cytology
sample.2 Careful measuring of MPM
tumor on computed tomography (CT)
scan of the chest is crucial not only at
initial diagnosis and staging but also
for correct identification of tumor
response to treatment. MPM may,
however, present not only as a well-
delineated and measurable pleural
thickening but sometimes also as a
much thinner, not really well-delin-
eated rind-like pleural involvement.
Occasionally, pleural involvement by
MPM is only macroscopically detect-
able during thoracoscopy and later
microscopically proven while the CT
imaging does not show any significant
pleural thickening at all. Differential
diagnosis between minimal benign
pleural thickening and MPM can in-
deed prove to be very challenging
based on CT scan only, and recently,
the additional value of the fluorode-
oxyglucose positron emission tomog-
raphy imaging combined with CT scan
has been demonstrated.2
What we actually missed in this
practical guideline by Tsao et al. were
the tips to “evaluate” MPM cases with
these radiologically minimal rind-like
thickenings or with occasional “non-
measurable” or “normal” pleural MPM
disease. When we participated in the
landmark MPM trial by Vogelzang et
al.,3 measurements of MPM pleural
involvement were uniformly per-
formed using the study protocol effi-
cacy criteria for tumor response as
modified from the preexisting South-
west Oncology Group standard tumor
response criteria published by Green
et al.4 Briefly, in patients with unidi-
mensionally measurable disease,
thickness of pleural rind had to be
measured at three separate levels on
transverse CT cuts. Levels should be
at least 2 cm apart from each other. At
each level, measurement of up to three
areas of pleural rind should be per-
formed where feasible. Measures
should not be made of pleural thicken-
ing that was less than 1 cm. If
bidimensionally measurable lesions
coexisted, these could be measured ac-
cording to RECIST criteria and the
measurements could be added to the
sum of the unidimensional measure-
ments. In 2004, these adapted or mod-
ified RECIST guidelines on how to
measure MPM tumors were published
in detail by Byrne et al.5
According to the Vogelzang trial
protocol, MPM disease status could be
defined not only as measurable disease
but sometimes also as “non-measurable”
or “evaluable” disease and rarely as
“nonevaluable” disease. Evaluable
disease was defined as pleural lesions
on CT scan with perpendicular diam-
eters smaller than 1.0 cm, as has been
also detailed in the practical guidelines
by Tsao et al.1 In this category of
evaluable or non-measurable rind-like
pleural thickenings also pleural thick-
ening secondary to previous talc
pleurodesis may be classified. It is
important, however, to document
evaluable MPM disease at baseline
and during treatment, because the evo-
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